tiprankstipranks
Faron Pharmaceuticals Announces H1 2024 Financials
Company Announcements

Faron Pharmaceuticals Announces H1 2024 Financials

Faron Pharmaceuticals Oy (GB:FARN) has released an update.

Don't Miss our Black Friday Offers:

Faron Pharmaceuticals Ltd., a biopharmaceutical company focused on novel cancer immunotherapies, is set to release its unaudited financial results for the first half of 2024 on August 27. The company will also host a live briefing and Q&A session on August 28, offering both webcast and a limited in-person attendance in Helsinki. Investors and media can find the half-year report and a replay of the briefing on Faron’s website, with the company’s lead asset, bexmarilimab, currently under clinical trials for hematological cancers.

For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskFaron Pharmaceuticals Expands Pipeline with New Patent
TipRanks UK Auto-Generated NewsdeskFaron Pharmaceuticals Updates Nomination Board Amid Cancer Drug Trials
TipRanks UK Auto-Generated NewsdeskFaron Pharmaceuticals Reveals Promising Trial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App